Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$CAPR Q3 '25 Earnings Results & Recap Capricor Therapeutics reported zero revenue (vs. $0.6M est.) and a net loss of $24.6M, or $0.54 per share (vs. -$0.57 est.), with top-line data from the Hope 3 phase 3 study expected in the coming weeks and a potential FDA review period of up to six months. The company ended the quarter with about $100M in cash.
3

Since Post

Full Details

Advertisement|Remove ads.